What are the precautions for using Zenocutuzumab?

Zenocutuzumab, as an innovative bispecific monoclonal antibody, is mainly used to treat patients with non-small cell lung cancer (NSCLC) and pancreatic cancer carrying NRG1 gene fusions. When using this drug, in addition to paying attention to its efficacy, precautions are also key to ensuring patient safety and efficacy. Here are some important considerations when using zetolizumab.
1. Monitoring of allergic reactions and infusion reactions
Zeltolizumab is a biologic agent that may cause allergic reactions and infusion-related reactions. Common allergic reactions include rash, dyspnea, anaphylactic shock, etc. Infusion reactions may manifest as fever, chills, nausea, etc. Therefore, patients need to be infused in a medical facility during each dose and require close monitoring especially during the early stages of treatment. If the patient experiences discomfort during the infusion, it must be reported in time, and medical personnel should take appropriate measures, such as suspending the infusion, slowing down the infusion speed, or giving anti-allergic drugs for intervention.
2. Monitoring of cardiac function

Like other treatments that target HER2, zetolizumab may have some effects on heart function. Patients taking this medication need regular heart function evaluations, especially those with a history of heart disease. Heart failure or myocardial damage are serious side effects that may occur during treatment. Clinically, you should pay close attention to the results of electrocardiogram, cardiac ultrasound and other related examinations. If the patient's cardiac function is found to decline significantly, the treatment plan should be adjusted promptly or the use of zetolizumab should be suspended.

3. Suppression of the immune system
Zeltolizumab works by modulating the immune system and therefore may affect immune function, leading to immunosuppression. Patients may face the risk of infection during use, including respiratory tract infection, urinary tract infection, etc. Particularly, patients with combined immune system diseases or who are receiving other immunosuppressive treatments should be cautious. Patients should promptly report any symptoms of infection to the doctor during treatment, such as fever, cough, frequent urination, etc. Immunosuppressed patients also need to avoid contact with people with infectious diseases and follow infection prevention measures.
4. Laboratory examination and monitoring of biochemical indicators
Regular monitoring of laboratory test results is very important during treatment with zetolizumab. Especially blood routine, liver and kidney function, blood sugar, electrolytes and heart function and other indicators. Zetolizumab may cause abnormalities in some laboratory indicators, such as thrombocytopenia, leukopenia, and elevated liver enzymes. These changes may indicate side effects or complications during treatment, and patients should undergo regular checkups as directed by their doctor. If obvious hematological or biochemical abnormalities occur, the treatment plan should be adjusted according to the doctor's recommendations.
5. Use by pregnant and lactating women
The safety of zetolizumab in pregnant and breastfeeding women has not been fully established. Therefore, pregnant and breastfeeding women should avoid using zetolizumab unless their doctor decides on treatment after evaluating the risks versus benefits. The drug may pose potential risks to the fetus, so a pregnancy test for pregnant women is required before treatment. If lactating women need to use zetolizumab, they should consider discontinuing breastfeeding or taking other contraceptive measures to prevent the drug from affecting the baby through milk.
6. Precautions for combination therapy
In clinical applications, zetolizumab may sometimes be used in combination with other treatments, such as chemotherapy, immunotherapy or other targeted drugs. A patient's response to treatment and risk of side effects may change during combination therapy, requiring more careful monitoring. The interaction of different drugs may affect the efficacy and even exacerbate side effects. Doctors should carefully select combination treatment options based on the patient's individual situation to avoid potential adverse reactions.
As a new drug for the treatment of NRG1 gene fusion-positive cancers, zetolizumab has significant efficacy, but the above-mentioned matters need to be paid attention to during use. When receiving treatment, patients should undergo detailed evaluation and regular examinations under the guidance of a doctor to ensure the safe use and maximum efficacy of the drug. At the same time, doctors and patients should pay attention to the occurrence of side effects and make timely adjustments to ensure the smooth progress of the treatment process.
Reference link: https://www.zailaboratory.com